Healthcare / Diagnostics & ResearchHKSE
$0.07
-0.00 (-1.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-32.3M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$139M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-21.3%
↓Gross Margin
31.2%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-24.0%
FCF CAGR
—
FCF margin
-0.8%
FCF / Net income
0.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $40.8M · net income $-47.5M · FCF $-322000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $40.8M | $40.8M | $233.7M | $223.9M | $92.9M |
| Net Income | $-47.5M | $-47.5M | $15.8M | $-25.2M | $-34.5M |
| EBITDA | $-43.3M | $-43.3M | $27.7M | $-26.4M | $-35.1M |
| EPS | -0.03 | -0.03 | 0.01 | -0.02 | -0.03 |
| Gross Margin | 31.2% | 31.2% | 16.2% | 5.4% | 14.8% |
| Operating Margin | -32.3% | -32.3% | 7.5% | -14.5% | -34.1% |
| Net Margin | -116.4% | -116.4% | 6.8% | -11.3% | -37.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.02 | 0.03 | 0.00 |
| Current Ratio | 2.94 | 2.94 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-322000.00 | $-322000.00 | $-32.3M | $-134.7M | $96.8M |
| Returns | |||||
| ROE | -21.3% | -21.3% | 5.9% | -10.6% | -13.1% |
| Valuation | |||||
| P/E | — | — | 8.23 | — | — |
| EV/EBITDA | — | — | 4.87 | — | — |
| P/B | 0.62 | 0.62 | 0.48 | 2.79 | 3.58 |
| Growth & Yield | |||||
| Revenue Growth | -82.6% | -82.6% | 4.4% | 141.0% | — |
| EPS Growth | -366.7% | -366.7% | 156.1% | 36.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-3.8%
Start / end P/E
n/dx → n/dx
EPS bridge
0.01 → -0.03
Residual
-3.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.